About cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A
cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A) is a protein
from Homo sapiens identified by UniProt accession
Q9Y233, 1055 residues long.
MolForge cross-references it against 0 known binders and
397 disease associations.
Target properties
| Protein name | cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A |
|---|
| UniProt accession | Q9Y233 |
|---|
| Gene | PDE10A |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1055 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (6)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (397)
Diseases linked to this target (Open Targets).
- infantile-onset generalized dyskinesia with orofacial involvement · score 0.73
- striatal degeneration, autosomal dominant 2 · score 0.60
- IGF-1 measurement · score 0.59
- coronary artery disease · score 0.55
- stroke · score 0.55
- cardiovascular disease · score 0.54
- body height · score 0.51
- striatal degeneration, autosomal dominant · score 0.50
- Hepatitis, Alcoholic · score 0.48
- diastolic blood pressure · score 0.48
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9Y233-F1 | alphafold | PREDICTED | 69.40 | — |
Amino-acid sequence (1055 residues)
MASLEEPLAP RPQGPLPAAG DEPGCGPGKL RPEPRLSAAG GGSAAGPGPA PEWPGRGRAE RAAPPRPPLS SAGRPSPAGG PGALSARGGG CGWVAARAPL ALAFSSRVPS SSPSFFYFWP PPPPPPPSFL PSSSAFHLPV RLPGREGAAA AAAAGGGGDA GGGGGGGQEA APLSVPTSSS HRGGGGSGGG RRRLFLSPAL QGLLLPARAG PRPPPPPRLP LGQAARRAGS PGFPGAGPGG GGQTPRRPQG ASFALAAAAA LLFGSDMEDG PSNNASCFRR LTECFLSPSL TDEKVKAYLS LHPQVLDEFV SESVSAETVE KWLKRKNNKS EDESAPKEVS RYQDTNMQGV VYELNSYIEQ RLDTGGDNQL LLYELSSIIK IATKADGFAL YFLGECNNSL CIFTPPGIKE GKPRLIPAGP ITQGTTVSAY VAKSRKTLLV EDILGDERFP RGTGLESGTR IQSVLCLPIV TAIGDLIGIL ELYRHWGKEA FCLSHQEVAT ANLAWASVAI HQVQVCRGLA KQTELNDFLL DVSKTYFDNI VAIDSLLEHI MIYAKNLVNA DRCALFQVDH KNKELYSDLF DIGEEKEGKP VFKKTKEIRF SIEKGIAGQV ARTGEVLNIP DAYADPRFNR EVDLYTGYTT RNILCMPIVS RGSVIGVVQM VNKISGSAFS KTDENNFKMF AVFCALALHC ANMYHRIRHS ECIYRVTMEK LSYHSICTSE EWQGLMQFTL PVRLCKEIEL FHFDIGPFEN MWPGIFVYMV HRSCGTSCFE LEKLCRFIMS VKKNYRRVPY HNWKHAVTVA HCMYAILQNN HTLFTDLERK GLLIACLCHD LDHRGFSNSY LQKFDHPLAA LYSTSTMEQH HFSQTVSILQ LEGHNIFSTL SSSEYEQVLE IIRKAIIATD LALYFGNRKQ LEEMYQTGSL NLNNQSHRDR VIGLMMTACD LCSVTKLWPV TKLTANDIYA EFWAEGDEMK KLGIQPIPMM DRDKKDEVPQ GQLGFYNAVA IPCYTTLTQI LPPTEPLLKA CRDNLSQWEK VIRGEETATW ISSPSVAQKA AASED
Explore cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets